Effect of Anemia on Short- and Long-Term Outcome in Patients Hospitalized for Acute Coronary Syndromes

Sex‐based differences in bleeding and long‐term adverse events after percutaneous coronary intervention in older patients with coronary artery disease

“…Although these findings are in accordance with previous studies, univariate and multi‐variable analyses indicated that these variables were not independent risk factors for 2‐year bleeding. Pre‐procedural anemia and renal dysfunction were previously shown to be independently associated with increased bleeding post‐PCI . In the present study, we did not transform the eGFR or hemoglobin into categorical variables such as chronic renal disease or anemia, which may have contributed to these contrasting findings.…”

“…Pre-procedural anemia and renal dysfunction were previously shown to be independently associated with increased bleeding post-PCI. 14,15 In the present study, we did not transform the eGFR or hemoglobin into categorical variables such as chronic renal disease or anemia, which may have contributed to these contrasting findings. We also found no differences in medical treatment between sexes, including use of medication with dual anti-platelets, anticoagulants, and GPIs.…”

2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

“…Niedokrwistość jest często obserwowana u pacjentów hospitalizowanych z powodu ACS, a jej częstość występowania waha się między 6,4% i 45% [499]. Utrzymująca się lub pogłę-biająca się niedokrwistość u pacjentów z ACS silnie wiąże się ze zwiększonym ryzykiem zgonu, ponownego MI i poważnych krwawień [500].…”

Outcomes of anemic patients presenting with acute coronary syndrome: An analysis of the Cooperative National Registry of Acute Coronary Care, Guideline Adherence and Clinical Events

“…[1][2][3][4][5][6] Numerous studies have shown that anemia is associated with poorer outcomes and those presenting with ACS and baseline anemia have a significantly increased risk of early and late mortality. 1,2,5,[7][8][9][10][11][12][13] Currently there are a wide range of therapies used to treat ACS including coronary angiography with revascularisation and the use of dual antiplatelet medications. There is a strong evidence base supporting their prognostic importance in the ACS cohort however many of these trials have excluded anemic patients.…”